Observational studyActa paediatrica (Oslo, Norway : 1992)2026
Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators.
Observational study in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimChildren with cystic fibrosis (CF) face substantial daily treatment burdens and the effects of transmembrane conductance regulator modulators on these have not been sufficiently described. We evaluated changes in treatment burden after elexacaftor tezacaftor ivacaftor (ETI) was initiated.
methodsThis prospective observational study comprised children aged six to 17 years from three Swedish paediatric CF centres. They were enrolled from 7 December 2022 to 30 June 2023, before ETI was initiated. Their health-related quality of life, treatment burden, and adherence were assessed at baseline and at six and 12 months.
resultsWe studied 62 children who initiated ETI and were followed up to 12 months. The mean standard deviation (SD) treatment burden score improved by 4.9 points (95% confidence interval (CI) -0.7 to 10.6, p = 0.087), from 67.6 (±20.6) at baseline to 72.5 (±17.6) at 12 months. The mean daily time spent on inhalation therapy and airway clearance decreased from 91.9 (±37.3) to 70.4 (±23.6) minutes (p < 0.001). Mean inhalation time per session fell by 7 min (95% CI -10.5 to -3.3, p < 0.001) and airway clearance time by 4 min (95% CI -6.7 to -1.5, p = 0.003).
conclusionTreatment burden, particularly daily inhalation and airway clearance time, decreased after ETI initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.